Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A microRNA signature identifies four subtypes of triple-negative breast cancer and correlates miR-342-3p as a regulator of the lactate metabolic pathway through silencing the monocarboxylate transporter 1

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): synthetic construct Homo sapiens

PROVIDER: GSE86948 | GEO | 2018/08/17

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

A microRNA signature identifies four subtypes of triple-negative breast cancer and correlates miR-342-3p as a regulator of the lactate metabolic pathway through silencing the monocarboxylate transporter 1

Project description:A microRNA signature identifies four subtypes of triple-negative breast cancer and correlates miR-342-3p as a regulator of the lactate metabolic pathway through silencing the monocarboxylate transporter 1

| PRJNA343043 | ENA

MicroRNA-342-3p is a regulator of hepatocellular carcinoma regression

Project description:Hepatocellular carcinoma (HCC) is a cancer with global impact and largely refractory to current treatments. Novel treatment options are therefore urgently needed. MicroRNAs play important regulatory roles in HCCs and are emerging as promising therapeutic options against HCC. We identified tumor suppressor miRNAs that may attenuate tumor development and contribute to HCC regression. We identified miR-342-3p as a promising tumor suppressor miRNA. To understand how miR-342-3p affects the global landscape of gene expression, we transfected Huh7 human hepatoma cells with either the scramble control, or a mimic for miR-342-3p and performed mRNA expression profiling.

2020-12-31 | GSE152950 | GEO

Epigenetic silencing of miR-342-3p in B cell lymphoma and its impact on autophagy.

Project description: Not available

| S-EPMC7574348 | biostudies-literature

Loss of function of miR-342-3p results in MCT1 over-expression and contributes to oncogenic metabolic reprogramming in triple negative breast cancer.

Project description: Not available

| S-EPMC6095912 | biostudies-literature

A microRNA signature identifies four subtypes of triple-negative breast cancer I

Project description:Triple negative breast cancer (TNBC) represents a challenging tumor type due to their poor prognosis and limited treatment options. It is well recognize that clinical and molecular heterogeneity of TNBC is driven in part by post-transcriptional regulators such as miRNAs. To stratify TNBCs, we profiled 1050 miRNAs in 132 adjuvant TNBC tumors and 40 tumors from other immunophenotypes using an Affymetrix microarray platform. A NMF clustering analysis allowed us to identify 4 TNBC subtypes featuring unique miRNA expression patterns, disease free and overall survival rates and particular gene ontology enrichments (performed with GSEA algorithm). Our agglomerative approach was cross-validated by using two other clustering algorithms (k-means and consensus clustering). TNBC miRNAs subgroups were also correlated with the Lehmann intrinsic subtypes, finding a significant enrichment of immmnomodulartory and basal 1 subtypes in our high risk miRNA subgroups. 3 cell line models (MDA MB 468, MDA MB 231 and HS578T) were classified according to our miRNA signature, recapitulating two different miRNA subgroups. The TNBC tumors were compared against other phenotypes identifying differentially expressed miRNAs that together with the altered miRNAs within the subgroups allowed us to define interesting miRNAs for further functional analysis.

2018-08-16 | GSE86277 | GEO

A microRNA signature identifies four subtypes of triple-negative breast cancer II

2018-08-16 | GSE86281 | GEO

Prognostic value of miR-221-3p, miR-342-3p and miR-491-5p expression in colon cancer.

Project description: Not available

| S-EPMC4113501 | biostudies-literature

Elevated circulating miR-150 and miR-342-3p in patients with irritable bowel syndrome.

Project description: Not available

| S-EPMC4119883 | biostudies-other

Identification of four subtypes of Triple Negative Breast Cancer (TNBC) by genomic profiling

Project description:The aggressive triple negative breast cancers (TNBCs), which lack estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), comprise a high-risk subset of human breast cancers which remain poorly characterized and lack effective treatments. While meta-analyses have recently suggested the complexity of these tumors, no robust phenotypes have been defined. We identified four distinct subtypes through gene expression analyses of 198 TNBCs (84 Discovery, 114 Validation). We then classified 221 publically available TNBCs profiled on the same mRNA expression array. All three sets supported stratification of tumors by cell cycle (Subtype 1 Luminal – FOXA1, LUM), DNA repair (Subtype 2, Mesenchymal – ADIPOQ, MES), downregulated immunological (Subtype 3, Basal-Like – SOX10/8, BL), and upregulated immunological (Subtype 4, Basal Immune – STAT1, BI) signaling pathways. Additional classified data sets demonstrate significantly lower risk of relapse and death with BI tumors, and highest risk with BL tumors, even after correction with known risk factors. DNA copy number profiling of our primary study set produced optimal differentiation of the LUM subtype from the remaining tumors, and drove expression of FGFR2 and CDK1 in BL and BI subtypes. Subtype-specific targets include MUC1 in LUM tumors, CTLA4 in BI tumors, and a potential dependence of MES tumors on NTRK2, DDR2, PDGFRA, TEK, and ADRB2, which, upon validation, could enable targeted treatment with tyrosine-kinase inhibitors and beta-blockers. These findings further define TNBCs and provide the rationale for studies targeting agents against these tumor subtypes, thereby enabling a higher potential for preventive efficacy in patients with TNBC.

2015-12-25 | GSE76339 | GEO

MicroRNA-342-3p is a regulator of hepatocellular carcinoma regression

Project description:MicroRNA-342-3p is a regulator of hepatocellular carcinoma regression

| PRJNA641039 | ENA